Shanghai Henlius Biotech EBIT

The latest EBIT for 2696.HK is $890M as of June 2026. That compares with $850M in the prior-year period — up 4.8% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside Shanghai Henlius Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, 2696.HK's EBIT moved from $850M to $890M — a 4.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Shanghai Henlius Biotech's operating scale or balance-sheet position.

Against Healthcare companies, 2696.HK currently prints $890M for EBIT, while the sector average sits near $130B. That is roughly 99.3% below the sector mean. Large gaps often invite a closer look at Shanghai Henlius Biotech's growth, margins, and balance sheet.

A EBIT figure of $890M for 2696.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting 2696.HK's EBIT ($890M), review year-over-year change from $850M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.